[ad_1]
“The technology for storing and exploiting synthetic datain order to be credible and usable in the medical-health field, it must be validated through very strong stress tests “, Della Porta points out. “L’hematologyin this sense, it is a perfect use case, because it allows you to work on real data and on a huge number of information that also comes from different clinical fields“. In addition to the advantages from the experimental point of view, the haematological field is in absolute need of new dataAnd “of a system of exploitation of the data that is more effective and more functional for the management of patients”he adds.
In particular, to begin with, two diseases were considered that from a clinical and treatment point of view are the polar opposite: a form of cancer such as acute leukemiawhich mainly affects adults, and one genetic disease such as sickle cell anemia, which emerges on a clinical level already in children. “The choice of two very distant fields of application was also made to demonstrate the versatility and the applicability of Synthema in different contexts”Continues Della Porta.
Hematology is just the beginning
We are a few days away from the actual launch of the project, scheduled for December 15. “The idea is to start with the part about leukemia because the clinical consortium is ready to share data and develop specific technologies”, Della Porta specifies. “It will not be a short path, 4 years are foreseen to complete the project: the first 2 for applications to specific case studies and another 2 for make the data storage and processing system plastic and adaptable to all sectors of medicine and not just hematology“. This is precisely because the goal is to create a tool that can work effectively for any area of medicine, by applying the paragidma of avatars and synthetic data to the most diverse clinical fields.
Each synthetic data, in the medical field, must obviously be validated in a similar way to the real data, so it is necessary to set a regulatory and bureaucratic process so that this information can then be used like that collected directly on patients in flesh and blood. All this, as anticipated, always in full compliance with the regulations on privacy.
In essence, it could be said that synthetic data is capable of multiply the information available and of also integrate those belonging to different assets, without creating contradictions or distortions in the content of the information itself. Beautiful in words, not so simple to make.
If all goes as desired, the most obvious advantages will be there especially for the particularly heterogeneous diseases from a clinical point of view, which have unique and variable characteristics. In these cases it is often difficult to find analogies with other patients, and consequently the data – at least as they have been understood up to now – fail to produce truly functional information. The other stated goal is to produce gods easily usable and comparable data. “The result of the elaboration process of a technology like the one we will develop must be simple information “concludes Della Porta, “certainly the result of a very complex computational process, but still of easy interpretation“.
.
[ad_2]
Source link
